Viewing Study NCT05296161

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:48 AM
Ignite Modification Date: 2026-01-27 @ 10:54 PM
Study NCT ID: NCT05296161
Status: RECRUITING
Last Update Posted: 2022-04-28
First Post: 2022-02-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
Sponsor: Amsterdam UMC, location VUmc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Sclerosis, Relapsing-Remitting View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ocrevus View
None ocrelizumab View
None personalised dosing View